Lista de obras - Michael W Ronellenfitsch

ANGI-02PERIOPERATIVE CEREBRAL ISCHEMIA PROMOTE INFILTRATIVE RECURRENCE IN GLIOBLASTOMA.

artículo científico publicado en 2015

Activation of AMP-activated kinase modulates sensitivity of glioma cells against epidermal growth factor receptor inhibition.

artículo científico publicado en 2016

Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death

artículo científico publicado en 2020

Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab

artículo científico publicado en 2019

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma

artículo científico publicado en 2018

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.

artículo científico publicado en 2009

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

artículo científico publicado en 2016

Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.

artículo científico publicado en 2017

Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?

artículo científico publicado en 2010

CASP9 germline mutation in a family with multiple brain tumors

artículo científico publicado en 2016

Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer

artículo científico publicado en 2020

Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas

artículo científico publicado en 2016

Disruption of peroxisome proliferator-activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells

scientific article published on 21 December 2018

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases

artículo científico publicado en 2015

Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems.

artículo científico publicado en 2018

EGFR and mTOR as therapeutic targets in glioblastoma

scientific article published on 30 July 2019

Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux.

artículo científico publicado en 2017

Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives ⬇️

artículo científico publicado el 19 de septiembre de 2010

Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid

artículo científico publicado en 2014

Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors

artículo científico publicado en 2015

Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas

scientific article published on 07 May 2019

Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death

artículo científico publicado en 2017

Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.

artículo científico publicado en 2016

P01.10METABOLIC CONDITIONS DETERMINE SENSITIVITY OF GLIOMA CELLS AGAINST EPIDERMAL-GROWTH FACTOR RECEPTOR (EGFR)-INHIBITION.

artículo científico publicado en 2014

Personalized translational epilepsy research - Novel approaches and future perspectives: Part I: Clinical and network analysis approaches.

artículo científico publicado en 2017

Personalized translational epilepsy research - Novel approaches and future perspectives: Part II: Experimental and translational approaches.

artículo científico publicado en 2017

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients

scientific article published on 21 November 2019

Rescue of 2-Deoxyglucose Side Effects by Ketogenic Diet

artículo científico publicado en 2018

Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment

artículo científico publicado en 2019

Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma

artículo científico publicado en 2014

Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death ⬇️

artículo científico publicado el 28 de noviembre de 2011

Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors

scientific article published on 04 February 2020

The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.

artículo científico publicado en 2010

The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma

artículo científico publicado en 2019

Treatment of refractory and superrefractory status epilepticus with topiramate: A cohort study of 106 patients and a review of the literature

scientific article published on 11 November 2019

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy

artículo científico publicado en 2013

Lista de obras de Michael W Ronellenfitsch

ANGI-02PERIOPERATIVE CEREBRAL ISCHEMIA PROMOTE INFILTRATIVE RECURRENCE IN GLIOBLASTOMA.

Activation of AMP-activated kinase modulates sensitivity of glioma cells against epidermal growth factor receptor inhibition.

Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death

Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.

Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?

CASP9 germline mutation in a family with multiple brain tumors

Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer

Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas

Disruption of peroxisome proliferator-activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases

Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems.

EGFR and mTOR as therapeutic targets in glioblastoma

Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux.

Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives ⬇️

Hypoxia enhances the antiglioma cytotoxicity of B10, a glycosylated derivative of betulinic acid

Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors

Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas

Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death

Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.

P01.10METABOLIC CONDITIONS DETERMINE SENSITIVITY OF GLIOMA CELLS AGAINST EPIDERMAL-GROWTH FACTOR RECEPTOR (EGFR)-INHIBITION.

Personalized translational epilepsy research - Novel approaches and future perspectives: Part I: Clinical and network analysis approaches.

Personalized translational epilepsy research - Novel approaches and future perspectives: Part II: Experimental and translational approaches.

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients

Rescue of 2-Deoxyglucose Side Effects by Ketogenic Diet

Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment

Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma

Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death ⬇️

Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors

The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.

The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma

Treatment of refractory and superrefractory status epilepticus with topiramate: A cohort study of 106 patients and a review of the literature

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy